• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Novartis's Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape Product Image

Novartis's Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape

  • ID: 1991657
  • September 2011
  • 6 pages
  • GlobalData

Novartis’s Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape

Summary

GlobalData, the industry analysis specialist, has released its new report, “Novartis’s Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape”. The report is an essential source of information and analysis on irritable bowel syndrome (IBS) market. The report provides insights on the Zelnorm commercialization. Most importantly, the report provides valuable insights on the Zelnorm life cycle and its market revenues. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the NSCLC market. Its scope includes -
- Treatment options in IBS market and role Zelnorm.
- Zelnorm clinical trials and its overall market events.
- Market revenues of Zelnorm
- Events leading to market withdrawl of Zelnorm

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop business strategies by understanding the Zelnorm’s commercialization story
- Leverage the opportunity of branding with key markets having high market potential
- Formulate effective marketing strategies from the learnings of Zelnorm
- Organize your sales and marketing efforts by identifying the key competitors

Note: Product cover images may vary from those shown

1
1

1.1 List of Tables
1.2 List of Figures
2 Summary
3 Novartis’s Zelnorm Suspension - Impact On The Irritable Bowel Syndrome (IBS) Treatment Landscape
3.1 Irritable Bowel Syndrome (IBS)
3.1.1 Treatment Overview
3.2 Zelnorm - Introduction in the IBS Therapeutics Market
3.2.1 What Led to the Approval - Clinical Trials
3.2.2 Drug Sales after Launch
3.3 Zelnorm - Withdrawal from the IBS Therapeutics Market after Serious Safety Threats
3.3.1 What Led to the Withdrawal - Earlier Warnings
3.4 Drug Sales of Zelnorm After Withdrawal
3.5 Zelnorm - After the Storm Settled
4 Appendix
4.1 Methodology
4.1.1 Coverage
4.1.2 Secondary Research
4.1.3 Primary Research
4.1.4 Expert Panel Validation
4.2 Contact Us
4.3 Disclaimer

1.1 List of Tables
Table 1: IBS Treatment options
Table 2: Revenue of Zelnorm in the IBS Therapeutics Market, 2002-2006
Table 3: Revenue of Zelnorm in the IBS Therapeutics Market, 2005-2008

1.2 List of Figures
Figure 1: Zelnorm Commercialization and Market Events
Figure 2: Revenue of Zelnorm in the IBS Therapeutics Market, 2002-2007
Figure 3: Revenue of Zelnorm in the IBS Therapeutics Market, 2005-2008
Figure 4: Lifecycle of Zelnorm Since Launch, Sales ($m)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos